Report from Annual General Meeting of Vitrolife AB (publ)
Rhea-AI Summary
Vitrolife AB held its Annual General Meeting on April 29, 2025, announcing key decisions including a dividend of SEK 1.10 per share for 2024. The board saw the re-election of members Henrik Blomquist, Lars Holmqvist, Pia Marions, Jón Sigurdsson, and Karen Lykke Sørensen, with Jón Sigurdsson elected as Chairman.
Board remuneration was increased to SEK 3.67 million, with the Chairman receiving SEK 1.35 million. The company authorized potential issuance of up to 13,544,719 shares (10% of share capital) and approved share buyback authorization. Deloitte AB was re-elected as auditor.
The meeting also approved new executive management compensation guidelines and resolved to enter a share swap agreement for LTIP 2025 implementation.
Positive
- Dividend payment of SEK 1.10 per share approved for 2024
- Board authorization to issue up to 13.5M new shares (10% of capital) for potential growth opportunities
- Increased board remuneration indicating company growth (total SEK 3.67M vs previous 3.3M)
Negative
- Potential shareholder dilution risk from 10% share issuance authorization
- Authorization for share buybacks up to 10% could reduce market liquidity
- Higher board compensation increases administrative expenses
- Resolution in accordance with the Board's proposed dividend of
SEK 1.10 per share for the financial year 2024. 2 May, 2025 was adopted as the record day. - Re-election of Board members Henrik Blomquist, Lars Holmqvist, Pia Marions, Jón Sigurdsson and Karen Lykke Sørensen, in accordance with the election committee's proposal. Jón Sigurdsson was elected Chairman of the Board.
- Remuneration to the Board members is proposed to be in total
SEK 3 670 000 (3 300 000) of whichSEK 1 350 000 (1 200 000) to the Chairman of the Board,SEK 450 000 (400 000) to each of the other members of the Board,SEK 160 000 (150 000) to the Chairman of the Audit Committee andSEK 80 000 (75 000) to each of the other members of the Audit Committee. - The Election Committee proposes re-election of the auditor Deloitte AB and with unchanged remuneration principles.
- Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve to issue a maximum of 13,544,719 shares in total, corresponding to just below 10 percent of the company's share capital.
- Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve on acquisition of the company's own shares. The Company can at no time hold more than 10 percent of the total shares in the Company.
- The proposed guidelines for remuneration and other conditions of employment for the executive management team were approved.
- Resolution to entering a share swap agreement in order to secure delivery of shares to participants in LTIP 2025 and the potential financial impacts of LTIP 2025.
VITROLIFE AB (publ)
The Board
The information was submitted for publication, through the agency of the contact persons set out above, at 29-04-2025 16:56 CET.
Contact:
Helena Wennerström, acting CFO, phone: +4670 822 80 86
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Report from Annual General Meeting of Vitrolife AB (publ) |
FAQ
What dividend did Vitrolife (VTRLY) announce for 2024?
How many shares is Vitrolife (VTRLY) authorized to issue in 2025?
What is the new Board compensation structure for Vitrolife (VTRLY) in 2025?
Who was elected as Vitrolife's (VTRLY) Board Chairman in 2025?
What share buyback limit was approved for Vitrolife (VTRLY)?
